Recent Updates — EIKN
Eikon Therapeutics presented updated efficacy and safety data from the TeLuRide-005 trial of its TLR7/8 dual-agonist EIK1001 at the 2026 European Society for Medical Oncology (ESMO) Congress. In the squamous non-small cell lung cancer cohort, the combination of EIK1001 with pembrolizumab and chemotherapy achieved a 72.4% objective response rate and a 100% disease control rate, with a median duration of response of 12.9 months. The pooled analysis across squamous and non-squamous cohorts showed a 63.1% overall response rate. The treatment was generally well-tolerated, supporting outpatient administration. Eikon is also conducting the Phase 2/3 TeLuRide-008 registrational trial, with an interim dose-selection analysis expected in the second half of 2027. Eikon Therapeutics operates as a late-stage clinical biopharmaceutical company developing innovative oncology medicines.
Eikon Therapeutics reported second quarter 2026 financial results and clinical updates. The company ended the quarter with $531.2 million in cash, cash equivalents, and marketable securities. Research and development expenses were $75.5 million, while general and administrative expenses decreased to $17.9 million due to prior-year impairment charges. Net loss attributable to common stockholders was $88.4 million. Clinically, EIK1001 advanced through a first interim analysis in the TeLuRide-006 registrational trial for melanoma, and seven abstracts were accepted for presentation at the ESMO Congress 2026. The company also appointed Ma. Fatima Francisco to its Board of Directors. Eikon Therapeutics is a late-stage clinical biopharmaceutical company developing innovative oncology medicines.
Eikon Therapeutics announced that Leon Chen and Joshua Wolfe resigned from its Board of Directors effective July 31, 2026. The company stated that their departures were not due to any disagreements regarding operations, policies, or practices. Eikon Therapeutics operates in the biotechnology industry, focusing on drug discovery.
Eikon Therapeutics, Inc. announced the appointment of Ma. Fatima D. Francisco to its Board of Directors as a Class I director, effective June 15, 2026. Ms. Francisco will serve until the 2027 annual meeting of stockholders, serving on the Compensation Committee. Her compensation package includes a $50,000 annual retainer and an option to purchase 85,937 shares of common stock at an exercise price of $8.96 per share. Eikon Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions through high-throughput screening technology.